Article
Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1.
Hepatology (Baltimore, Md.) - 1 Jan 2016
Perin Paula M, Haid Sibylle, Brown Richard J P, Doerrbecker Juliane, Schulze Kai, Zeilinger Carsten, von Schaewen Markus, Heller Brigitte, Vercauteren Koen, Luxenburger Eva, Baktash Yasmine M, Vondran Florian W R, Speerstra Sietkse, Awadh Abdullah, Mukhtarov Furkat, Schang Luis M, Kirschning Andreas, Müller Rolf, Guzman Carlos A, Kaderali Lars, Randall Glenn, Meuleman Philip, Ploss Alexander, Pietschmann Thomas
Abstract excerpt
UNLABELLED: To explore mechanisms of hepatitis C viral (HCV) replication we screened a compound library including licensed drugs. Flunarizine, a diphenylmethylpiperazine used to treat migraine, inhibited HCV cell entry in vitro and in vivo in a genotype-dependent fashion. Analysis of mosaic viruses between susceptible and resistant strains revealed that E1 and E2 glycoproteins confer susceptibility to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.